A. Antonelli, P. Fallahi, S. Ferrari, A. Corrado, M. Sebastiani, A. Manfredi, S. Frascerra, M. Miccoli, A. Zignego, E. Ferrannini, C. Ferri
Department of Internal Medicine University of Pisa School of Medicine, Pisa, Italy. firstname.lastname@example.org
2012 Vol.30, N°6 - PI 0864, PF 0870
Free to view (click on article PDF icon to read the article)
No study evaluated circulating chemokine (CXC motif) ligand (CXCL)9 in `patients with mixed cryoglobulinaemia and hepatitis C virus chronic infection` (MC+HCV). We aimed to measure CXCL9, IFN-γ and TNF-α in a series of MC+HCV to correlate these parameters to different clinical phenotypes.
Serum CXCL9, IFN-γ and TNF-α were assayed in 54 MC+HCV, in 54 patients with HCV chronic infection (HCV+) and in 54 sex- and age-matched controls.
MC+HCV showed significantly higher mean CXCL9 than HCV+ patients (p=0.01; ANOVA) or controls (p=0.0001; ANOVA), in particular in 21 cryoglobulinaemic patients with active vasculitis compared to those without (p<0.001; ANOVA). Serum IFN-γ (in patients with detectable IFN-γ) and TNF-α were significantly higher in MC+HCV than in controls (p<0.05, Mann-Whitney U test; p<0.0001, Mann-Whitney U-test; respectively). CXCL9, evaluated by classes of IFN-γ (IFN-γ<2; 2
We demonstrated markedly high serum levels of CXCL9 in MC+HCV (vs. HCV+ patients or healthy controls), significantly associated with the presence of active vasculitis. A strong relation among high levels of circulating IFN-γ, TNF-α and serum CXCL9 has been shown in MC+HCV. Larger patients` series will be needed to evaluate the relevance of serum CXCL9 determination as clinico-prognostic marker of MC+HCV.
PMID: 22766105 [PubMed]
Received: 06/09/2011 - Accepted : 24/01/2012 - In Press: 17/12/2012 - Published: 17/12/2012